⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0001611506

Cross Stefan

Reports to the SEC for 1 company · RALEIGH, NC

Transactions

7

Companies

1

Filings

4

CIK

0001611506

Forms 4 and 5

Insider transactions

7 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2017-12-19	INTIInhibitor Therapeutics, Inc.P Purchase	Director	PPurchase	−600K sh	$162660.00	−$97.6B	0
2017-03-08	INTIInhibitor Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+300K sh	—	—	300,000
2017-03-08	INTIInhibitor Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+300K sh	—	—	600,000
2017-03-08	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−300K sh	—	—	0
2017-03-08	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−300K sh	—	—	0
2015-08-14	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+300K sh	—	—	300,000
2014-07-18	INTIInhibitor Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+300K sh	—	—	300,000

Recent filings

4

Accepted (ET)
Feb 124
Cross Stefan0001144204-18-007442
SEC(opens sec.gov)
Mar 104
HedgePath Pharmaceuticals, Inc.0000899243-17-007151
SEC(opens sec.gov)
Aug 184
HedgePath Pharmaceuticals, Inc.0000899243-15-003422
SEC(opens sec.gov)
Feb 65
HedgePath Pharmaceuticals, Inc.0001209191-15-010358
SEC(opens sec.gov)

Companies

1

Inhibitor Therapeutics, Inc.DirectorINTI

Address

503 GUILFORD CIRCLE

RALEIGH, NC, 27608